Rexahn Pharmaceuticals, Inc.  

(Public, NYSEMKT:RNN)   Watch this stock  
Find more results for NYSEAMEX:RNN
0.673
-0.013 (-1.97%)
Nov 28 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.67 - 0.69
52 week 0.39 - 1.85
Open 0.68
Vol / Avg. 240,777.00/605,066.00
Mkt cap 122.28M
P/E     -
Div/yield     -
EPS -0.11
Shares 178.25M
Beta 0.99
Inst. own 8%
Nov 24, 2014
Rexahn Pharmaceuticals Inc at Brean Capital's Life Sciences Summit Conference
Nov 13, 2014
Q3 2014 Rexahn Pharmaceuticals Inc Earnings Release
Nov 5, 2014
Rexahn Pharmaceuticals Inc at EBD Group BIO-Europe Conference
Oct 7, 2014
Rexahn Pharmaceuticals Inc at BIO Investor Forum
Sep 9, 2014
Rexahn Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -20.19% -55.11%
Return on average equity -25.95% -85.74%
Employees 16 -
CDP Score - -

Address

Suite 455, 15245 Shady Grove Road
ROCKVILLE, MD 20850
United States - Map
+1-240-2685300 (Phone)
+1-240-2685310 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�s pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�s drug candidate, Archexin is an anticancer Akt inhibitor.

Officers and directors

Chang H. Ahn Chairman of the Board, Chief Scientist
Age: 62
Bio & Compensation  - Reuters
Rakesh Soni President, Chief Operating Officer
Age: 58
Bio & Compensation  - Reuters
Peter D. Suzdak Ph.D. Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Tae Heum Jeong Chief Financial Officer, Secretary
Age: 43
Bio & Compensation  - Reuters
Charles G. Beever Independent Director
Age: 61
Bio & Compensation  - Reuters
Peter C. Brandt Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark P. Carthy Independent Director
Age: 53
Bio & Compensation  - Reuters
Kwang Soo Cheong Independent Director
Age: 53
Bio & Compensation  - Reuters
Si Moon Hwang Independent Director
Age: 45
Bio & Compensation  - Reuters